A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Inclusion Criteria:
Diagnosis of migraine at ≤ 50 years of age (ICHD-II, 2004 Section 1)
History of migraine ≥ 12 months with
No use of any botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck 4 months prior to screening and during the 28 day period prior to randomization
Headache eDiary was completed on at least 25 of the 28 days prior to randomization
Exclusion Criteria: